Maravai LifeSciences Holdings, Inc. Stock

Equities

MRVI

US56600D1072

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-12 pm EDT 5-day change 1st Jan Change
8.4 USD -2.21% Intraday chart for Maravai LifeSciences Holdings, Inc. +5.66% +28.24%
Sales 2024 * 272M Sales 2025 * 301M Capitalization 1.11B
Net income 2024 * -13M Net income 2025 * -1M EV / Sales 2024 * 4.03 x
Net cash position 2024 * 12.58M Net cash position 2025 * 93.31M EV / Sales 2025 * 3.39 x
P/E ratio 2024 *
-82.5 x
P/E ratio 2025 *
-163 x
Employees 650
Yield 2024 *
-
Yield 2025 *
-
Free-Float 42.75%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.21%
1 week+5.66%
Current month-3.11%
1 month+6.33%
3 months+29.03%
6 months+8.11%
Current year+28.24%
More quotes
1 week
7.79
Extreme 7.79
8.73
1 month
7.10
Extreme 7.095
8.92
Current year
5.05
Extreme 5.045
8.92
1 year
4.52
Extreme 4.52
16.62
3 years
4.52
Extreme 4.52
63.55
5 years
4.52
Extreme 4.52
63.55
10 years
4.52
Extreme 4.52
63.55
More quotes
Managers TitleAgeSince
Chief Executive Officer 49 22-09-29
Founder 66 14-02-28
Director of Finance/CFO 53 17-04-30
Members of the board TitleAgeSince
Director/Board Member 57 16-02-29
Director/Board Member 48 16-02-29
Director/Board Member 60 19-12-31
More insiders
Date Price Change Volume
24-04-12 8.4 -2.21% 1,257,184
24-04-11 8.59 -0.12% 1,563,510
24-04-10 8.6 +1.06% 2,264,089
24-04-09 8.51 +8.13% 1,817,350
24-04-08 7.87 -1.01% 1,738,588

Delayed Quote Nasdaq, April 12, 2024 at 04:00 pm EDT

More quotes
Maravai LifeSciences Holdings, Inc. is a life sciences company. The Company provides products that enable the development of drug therapies, diagnostics and vaccines and to support research on human diseases. Its companies provide products and services in the fields of nucleic acid synthesis and biologics safety testing to various biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies. The Company operates through two segments. Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acid products to support the needs of customer research, therapeutic and vaccine programs. The segment also provides research products for labeling and detecting proteins in cells and tissue samples. Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
8.4 USD
Average target price
9.785 USD
Spread / Average Target
+16.48%
Consensus